In a filing, UroGen Pharma Ltd revealed its Chief Medical Officer Schoenberg Mark unloaded Company’s shares for reported $50698.0 on Jan 31 ’25. In the deal valued at $11.14 per share,4,551 shares were sold. As a result of this transaction, Schoenberg Mark now holds 145,666 shares worth roughly $1.4 million.
Then, Smith Jason Drew sold 7,379 shares, generating $82,202 in total proceeds. Upon selling the shares at $11.14, the General Counsel now owns 26,468 shares.
Before that, Schoenberg Mark sold 859 shares. UroGen Pharma Ltd shares valued at $11,236 were divested by the Chief Medical Officer at a price of $13.08 per share. As a result of the transaction, Schoenberg Mark now holds 145,091 shares, worth roughly $1.39 million.
A number of analysts have revised their coverage, including Guggenheim’s analysts, who began to cover the stock in late August with a ‘”a Buy”‘ rating. Jefferies also remained covering URGN and has decreased its forecast on February 08, 2023 with a “Hold” recommendation from previously “Buy” rating. Berenberg started covering the stock on April 27, 2022. It rated URGN as “a Buy”.
Price Performance Review of URGN
On Tuesday, UroGen Pharma Ltd [NASDAQ:URGN] saw its stock jump 3.56% to $9.60. Over the last five days, the stock has gained 0.95%. UroGen Pharma Ltd shares have fallen nearly -9.86% since the year began. Nevertheless, the stocks have fallen -47.63% over the past one year. While a 52-week high of $20.70 was reached on 02/05/25, a 52-week low of $9.03 was recorded on 02/28/25. SMA at 50 days reached $10.51, while 200 days put it at $12.99.
Levels Of Support And Resistance For URGN Stock
The 24-hour chart illustrates a support level at 9.22, which if violated will result in even more drops to 8.84. On the upside, there is a resistance level at 9.82. A further resistance level may holdings at 10.04. The Relative Strength Index (RSI) on the 14-day chart is 40.29, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.56, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 72.33%. Stochastics %K at 20.06% indicates the stock is a holding.
The most recent change occurred on April 16, 2020 when H.C. Wainwright resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $57.
